AtlasXomics Inc.

AtlasXomics, a 2020 Yale spin-out, is helping researchers understand the delicate epigenetic interplay and networks between cell types in their native environment that drives pathogenesis. We have helped over 50 investigators in oncology, aging, and neuroscience among other fields to locate and characterize driving epigenetic mechanisms in the tissue microenvironment. These mechanisms underly disease states and treatment responses. AtlasXomics combines epigenomics (spatial ATAC-seq and spatial CUT&Tag) with histology to provide insight that is often missed by bulk or single cell genomic tools. Our technology is primed for multi-omics studies in the same tissue section that uniquely positions us to identify and verify functional epigenetic mechanisms with proteome and transcriptome output. Mapping the cellular environment with an unbiased epigenome focus is needed to bring research closer to ground truth in diseased tissue to improve success rates for therapeutic interventions.